Lantheus Holdings, Inc. (LNTH) FY2025 10-K Annual Report
Lantheus Holdings, Inc. (LNTH) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Lantheus Holdings, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Development, manufacturing, and commercialization of radiopharmaceutical and diagnostic imaging products
- • New launches: Acquisitions of Life Molecular (Neuraceq) and Evergreen, adding diagnostic imaging and CDMO services to portfolio in 2025
Management Discussion & Analysis
- • Operating cash flow $390.1M in 2025 vs $544.8M in 2024, decrease driven by acquisitions and working capital timing
- • Investing cash outflow $627.1M in 2025 vs $204.5M in 2024, 2025 includes $268.9M for Evergreen and $306.7M for Life Molecular acquisitions
Risk Factors
- • No specific or timely regulatory or legal risk detailed in the text
- • No concrete geopolitical or macroeconomic threat exposure disclosed
Lantheus Holdings, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$1.5B
▲ +0.5% YoY
Net Income
$234M
▼ -25.2% YoY
Gross Margin
61.1%
▼ -333bp YoY
Operating Margin
20.2%
▼ -963bp YoY
Net Margin
15.2%
▼ -522bp YoY
ROE
21.4%
▼ -729bp YoY
Total Assets
$2.2B
▲ +12.5% YoY
EPS (Diluted)
$3.41
▼ -21.8% YoY
Operating Cash Flow
$390M
▼ -28.4% YoY
Source: XBRL data from Lantheus Holdings, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Lantheus Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.